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Abstract
Introduction Critically ill patients can develop hyperglycaemia
even if they do not have diabetes. Intensive insulin therapy
decreases morbidity and mortality rates in patients in a surgical
intensive care unit (ICU) and decreases morbidity in patients in
a medical ICU. The effect of this therapy on patients in a mixed
medical/surgical ICU is unknown. Our goal was to assess
whether the effect of intensive insulin therapy, compared with
standard therapy, decreases morbidity and mortality in patients
hospitalised in a mixed ICU.
Methods This is a prospective, randomised, non-blinded, single-
centre clinical trial in a medical/surgical ICU. Patients were
randomly assigned to receive either intensive insulin therapy to
maintain glucose levels between 80 and 110 mg/dl (4.4 to 6.1
mmol/l) or standard insulin therapy to maintain glucose levels
between 180 and 200 mg/dl (10 and 11.1 mmol/l). The primary
end point was mortality at 28 days.
Results Over a period of 30 months, 504 patients were
enrolled. The 28-day mortality rate was 32.4% (81 of 250) in the
standard insulin therapy group and 36.6% (93 of 254) in the
intensive insulin therapy group (Relative Risk [RR]: 1.1; 95%
confidence interval [CI]: 0.85 to 1.42). The ICU mortality in the
standard insulin therapy group was 31.2% (78 of 250) and
33.1% (84 of 254) in the intensive insulin therapy group (RR:
1.06; 95%CI: 0.82 to 1.36). There was no statistically
significant reduction in the rate of ICU-acquired infections:
33.2% in the standard insulin therapy group compared with
27.17% in the intensive insulin therapy group (RR: 0.82;
95%CI: 0.63 to 1.07). The rate of hypoglycaemia (≤ 40 mg/dl)
was 1.7% in the standard insulin therapy group and 8.5% in the
intensive insulin therapy group (RR: 5.04; 95% CI: 1.20 to
21.12).
Conclusions IIT used to maintain glucose levels within normal
limits did not reduce morbidity or mortality of patients admitted
to a mixed medical/surgical ICU. Furthermore, this therapy
increased the risk of hypoglycaemia.
Trial Registration clinicaltrials.gov Identifiers: 4374-04-13031;
094-2 in 000966421Page 1 of 9
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APACHE II: Acute Physiology and Chronic Health Evaluation; CDC: Centers for Disease Control; 95% CI: 95% confidence interval; HPTU: Hospital 
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Hyperglycaemia is frequently found in critically ill patients even
in the absence of diabetes and it is associated with a poor
prognosis [1-4]. A randomised trial of 1548 patients hospital-
ised in a surgical intensive care unit (ICU) showed that main-
taining normal glucose levels reduces morbidity and mortality
[5]. In another randomised study of 1200 patients requiring a
minimum of three days hospitalisation in a medical ICU, inten-
sive glucose control resulted in a decrease in morbidity but not
in total mortality. However, a decrease in mortality was
observed in a subgroup of patients treated with intensive con-
trol for three or more days [6].
Observational studies have suggested that strict glucose con-
trol is able to reduce hospital mortality in mixed medical/surgi-
cal ICUs [7,8], but other non-experimental studies in similar
settings have not confirmed that the mean glucose level is an
independent risk factor for ICU mortality. [9-11].
It remains unclear if intensive insulin therapy is equally effica-
cious in both medical and surgical patients [12]. Therefore, we
conducted a randomised clinical trial to assess the efficacy
and safety of intensive insulin therapy compared with standard
glucose control in patients hospitalised for medical problems,




Patients aged 15 years or older admitted to the ICU at the
Hospital Pablo Tobón Uribe (HPTU), Medellín, Colombia,
between 12 July, 2003 and 21 December, 2005 with an
expected ICU stay of at least two days were eligible for the
trial. HPTU is a 239-bed university hospital with a mixed (sur-
gical/medical) 12-bed adult ICU. Reasons for exclusion were
pregnancy, diabetic ketoacidosis, hyperosmolar non-ketotic
state, readmission to the ICU during the same hospitalisation,
advanced stage cancer (solid or haematological), decision to
withhold or withdraw aggressive therapies, and inclusion in
another clinical trial.
The protocol was approved by the institution's ethics commit-
tee and written informed consent was obtained from the
patients or their closest relatives. An independent Data Safety
Monitoring Board comprised of three members with expertise
in statistics, critical care and clinical epidemiology conducted
two interim analyses. The end points for efficacy were based
on the O'Brien-Flemming procedure with p values of 0.0006
and 0.0151. In both analyses they recommended to continue
the trial.
Randomisation
Patients were randomly assigned into study groups with a 1:1
ratio according to a computer-generated random number list
with permuted blocks of six. They were stratified by diabetes
diagnosis. The procedure was managed in the central phar-
macy in charge of group assignment. Personnel involved in the
treatment and investigation were unaware of the randomised
schedule and the block size.
Interventions
Patients were randomly assigned to receive either standard
insulin therapy or intensive insulin therapy. Both groups
received insulin via continuous infusion pump (Baxter col-
league 3 or Baxter flo-Gard 6301, Baxter Healthcare Corpora-
tion I. V. System Division, Deerfield, IL, USA). The standard
concentration of insulin (Humulin R, Eli Lilly and Company,
Indianapolis, IN, USA) was 100 units in 100 ml of 0.9% saline
solution. In the standard insulin group, insulin infusion was
started when glucose levels exceeded 215 mg/dl and was
adjusted to maintain blood glucose levels between 180 and
200 mg/dl (10.0 to 11.1 mmol/L) (See additional data file 1).
In the intensive insulin group, insulin infusion was started when
blood glucose levels exceeded 110 mg/dL, and was adjusted
to maintain a glucose level of between 80 and 110 mg/dl (4.4
to 6.1 mmol/L) (See additional data file 2).
Blood glucose levels were measured in undiluted arterial
blood. Undiluted samples were obtained by removing at least
four times the flush-volume in the line between the sampling
point and the arterial puncture site before the actual sample
was taken or, when an arterial catheter was not available, in
capillary blood with the use of a point-of-care glucometre
(MediSense Optium, Abbot Laboratories MediSense Prod-
ucts Bedford, MA, USA). Glucose levels were determined with
a glucometre at admission to ICU. They were repeated every
one, two and four hours if the patient had insulin infusion, and
every four and six hours if no insulin was required according to
the algorithm.
A protocol (see additional data files 1 and 2), managed by the
ICU nurses, was used for the adjustment of the insulin dose.
The standard insulin therapy had been the usual treatment dur-
ing the past 12 months, and a training period of three months
in the intensive insulin therapy was implemented before start-
ing the trial.
To prevent hypoglycaemia in patients who were receiving insu-
lin but were not receiving enteral or total parenteral nutrition,
10% glucose was administered intravenously via continuous
infusion (5 g/hour). The same infusion was used in patients
with diabetes who were not receiving nutrition in order to pre-
vent ketosis. It was also used for treatment of hypoglycaemic
patients (glucose was administered via a 10 g intravenous
boluses). The glucose infusion was stopped when the
patient's nutrition was restarted or when the patient was no
longer hypoglycaemic.
Protocols were consistently followed throughout the patient's
whole ICU stay. After discharge from the ICU, treatment wasPage 2 of 9
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tions and protocols were stopped.
We registered every patient's age, sex, body mass index, dia-
betes history, type of diabetes treatment, previous infections,
comorbidities, ICU admitting diagnosis, Acute Physiology and
Chronic Health Evaluation (APACHE II) score [13], Sequential
Organ Failure Assessment (SOFA) score [14] and Glasgow
coma score. The Glasgow coma score was obtained before
starting sedation and was changed only when the sedation
effects had finished.
Blood glucose levels were measured on admission. They were
also measured daily in the mornings. The median of all daily
values and daily maximal and minimal blood glucose levels
were documented. Hypoglycaemic episodes of less than 41
mg/dl (2.2 mmol/l) and within 41 to 59 mg/dl (2.2 to 3.2 mmol/
l) were registered, as well as the use of vasopressors, inotrop-
ics, steroids, transfusions, values of Glasgow trauma score,
daily number of glucometre readings, creatinine levels and the
SOFA scores.
If a patient presented with a temperature of 38.3°C or more or
if the treating physician suspected an infection, blood, urine
and sputum cultures were obtained. The diagnosis of infec-
tions acquired in the ICU was performed according to the
CDC diagnosis criteria applied by three different physicians
blinded to the treatment assignment [15]. A distinction was
made between primary and secondary bacteraemia, depend-
ing on whether or not a focus could be identified.
Outcomes
The primary outcome was 28-day all-cause mortality. Second-
ary outcomes were: ICU mortality; hospital mortality; incidence
of infections in the ICU (ventilator-associated pneumonia, uri-
nary infections, catheter-related infections and primary bacter-
aemias); ICU length of stay; days of mechanical ventilation and
incidence of severe hypoglycaemia defined as number of
patients with at least one episode of blood glucose level less
than 40 mg/dl (2.2 mmol/l).
Figure 1
Flow of participants through the trial.Page 3 of 9
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We estimated that the enrollment of 504 patients would pro-
vide a power of 80% to detect an absolute reduction of 10%
in the 28-day mortality rate with an alpha error (two-sided test)
of 0.05. We assumed a 25% mortality rate in the control
group.
Statistical analysis
Data is presented in absolute numbers and proportions for
nominal variables. Mean ± standard deviation (SD) or median
and interquartile range (IQR) is used for continuous variables,
normally or non-normally distributed, respectively.
The outcomes were analysed according to the intention-to-
treat principle. Primary and secondary end points were com-
pared with the use of a Student's t-test for parametric data, the
Mann-Whitney U test for non-parametric data, and the Pear-
son chi-square or Fisher exact test for proportions. For rates of
mortality, 95% confidence intervals (CI) were calculated, and
a p < 0.05 was considered statistically significant. No correc-
tions were made for multiples tests. The statistical analyses
were executed with the statistics packet SPSS/PC 13.0
(SPSS Inc., Chicago, IL, USA).
Results
During the study period 1643 patients were admitted to the
ICU and 831 did not meet inclusion criteria: 791 had an
expected length of stay in the ICU of less than 48 hours and
40 exceeded the recruitment time limit. Of the 812 patients
who met the inclusion criteria, 308 were excluded for the fol-
lowing reasons: 221 had a terminal illness, 42 refused to par-
ticipate, 40 had a second admission to the ICU and five had
diabetic ketoacidosis or hyperosmolar coma. A total of 504
patients were enrolled, 250 in the control group and 254 in the
intervention group. There was one patient from the intensive
insulin group who did not receive either of the two protocols
and one patient who belonged to the intensive insulin group
who received the conventional insulin protocol. According to
the intention-to-treat principle, they were analysed in the group
they had been assigned to originally. The patients were fol-
lowed-up until discharged from the hospital (Figure 1).
Demographics and baseline characteristics were similar in the
two groups (Table 1). The average delay between admission
to the ICU and enrollment into a protocol group was 12.5 ±
6.2 hours in the intensive insulin group and 12.4 ± 5.9 hours
in the standard insulin group (p = 0.853). The mean time
Table 1
Baseline characteristics of the patients.
Variable Standard treatment Intensive treatment
(N = 250) (N = 254)
Male sex (%) 154 (62) 147 (58)
Age (years)* 47.4 ± 19.3 45.9 ± 20.2
Body-mass index *† 25 ± 4.5 24.6 ± 4,2
History of diabetes (%) 29 (11.6) 32 (12.6)
Treated with insulin 9 (3.6) 5 (2.1)
Histrory cirrhosis 7 (2.8) 9 (3.5)
History heart failure 3 (1.2) 6 (2.4)
History kidney failure 16 (6.4) 10 (3.9)
History of cancer 9 (3.6) 15 (5.9)
APACHE II – score *‡ 15.6 ± 7.6 15.7 ± 6.9
SOFA – scores *§ 7.6 ± 3.5 7.3 ± 3.2
Reason for ICU admission (%)
Medical 123 (49.2) 123 (48.4)
Surgery 37 (14.8) 45 (17.7)
Trauma 90 (36) 86 (33.9)
Blood glucose on admission (mg/dl) *¶ 153.6 ± 67.1 155.3 ± 68.4
* Values presented as mean ± SD.
†The body mass index is the weight in kilograms divided by the square of the height in metres.
‡APACHE II = Acute Physiology and Chronic Health Evaluation. Higher scores reflects more severe critical illness.
§SOFA = Sequencial Organ Failure Assessment. Higher scores reflect more severe organic dysfunction. for the worst values in the six organs 
during the first 24 hours after enrollment.
¶To convert the values for glucose to millimoles per litre, multiply by 0.05551.Page 4 of 9
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intensive insulin group and 6.1 ± 2.5 hours in the standard
insulin group (p = 0.332).
Admissions due to infections were similar in both groups: 82
patients of 250 (32.8%) in the standard insulin group and 83
of 254 (32.7%) in the intensive insulin group.
The mean calorie intake in 24 hours was 23.1 ± 12.7 kcal/kg
in the standard insulin group and 25.5 ± 14.4 kcal/kg in the
intensive insulin group (mean difference: 2.4; 95% CI: -0.02 to
4.9). Total parenteral nutrition (glucose 30 to 50% plus amino
acids and lipids to reach the required total caloric intake) alone
or combined with enteral nutrition was given to 14 patients in
the standard insulin group (5.6%) and 14 in the intensive insu-
lin group (5.5%). The remaining patients received total-enteral
feeding exclusively. In the standard insulin group 47% patients
(118 of 250) received at least six hours intravenous 10% glu-
cose (5 g/hour) during the ICU stay (Figure 2).
More patients in the intensive insulin group than in the stand-
ard insulin group received insulin (97% vs. 47%, p < 0.001)
as well as having a higher amount of insulin administered per
24 hours (52.4 ± 53.3 IU vs. 12.5 ± 32.8 IU, p < 0.001). The
intensive insulin group had lower mean blood glucose level
than the standard insulin group: 117 mg/dl (IQR: 101 to 140)
compared with 148 mg/dl (IQR: 122 to 180), (p < 0.001) (Fig-
ure 3), and had more glucometre readings per day: 13 ± 5.5
compared with 5.9 ± 4.0, p < 0.001. The proportion of
patients with at least one episode of a glucose level of 40 mg/
dl or less was higher in the intensive insulin group (8.3% vs.
0.8%, p < 0,001). Six patients in the intensive insulin group
had two or more hypoglycaemic events (Table 2). One patient
presented with an episode of tonic-clonic generalised seizure
Figure 2
Nutrition administered to all 504 patients during the first 10 days of intensive careit on administ red to all 504 patients during the first 10 days 
of intensive care. Feeding at 0 represents the administration of nutri-
tion between admission and 7 a.m., and 1 represents feeding on the 
first day after admission, from 7 a.m. onwards. Nutrition in the two 
groups was similar. (a) Total caloric intakes areexpressed as mean val-
ues (with the 95% confidence intervals indicated by the error bar). (b) 
Nutrition administered by the enteral route are expressed as mean val-
ues, (with the 95% confidence intervals indicated by the error bar). (c) 
Nutrition administered by the parenteral route are expressed as mean 
values (with the 95% confidence intervals indicated by the error bar).
Figure 3
Daily blood glucose levels during the first 10 days of intensive carel  lood glucose levels during the first 10 days of intensive 
care. Medians and interquartile ranges (IQR) during the ICU stay (time) 
are shown for the two treatment arms.Page 5 of 9
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with insulin suspension and the administration of 200 cc 10%
glucose bolus with good response and no neurological dam-
age.
The median length of stay in the ICU, the duration of mechan-
ical ventilation and the rate of ICU-acquired infections were
not reduced by intensive insulin therapy. The use of medica-
tions other than insulin was the same for both groups. No dif-
ferences were found in new onset acute renal failure,
requirement of haemodialysis or red blood cell transfusions
(Table 3).
All-cause mortality at 28 days was 32.4% (81 of 250) in the
standard insulin group and 36.6% (93 of 254) in the intensive
insulin group. ICU mortality was similar for patients of the
standard insulin group and in those from the intensive insulin
group: 78 of 250 patients (31.2%) and 84 of 254 (33.1%),
respectively. Hospital mortality was also similar between the
standard insulin group and the intensive insulin group: 96 of
250 (38.4%) and 102 of 254 (40.2%), respectively (Table 4).
Discussion
We found that intensive glucose control did not reduce the
morbidity or the mortality of patients admitted to a mixed med-
ical/surgical ICU with medical problems, non-cardiovascular
surgeries or trauma. These results differ from two previous
studies. The first one with patients in a cardiovascular-surgical
ICU [5] demonstrated a decrease in morbidity and mortality.
The other in patients in a medical ICU demonstrated a
decrease in morbidity; however, a decrease in mortality was
only seen in a subgroup of patients with an ICU stay longer
than two days [6].
A possible explanation for these differences could be the dif-
ferent type of patients in each study. The first study was con-
ducted in a surgical ICU where 63% of the patients had
cardiovascular problems. In these patients, the decrease in
mortality recorded for the intensive insulin group was associ-
ated with a decrease in both the frequency of infections (46%)
and in the number of deaths due to multiple organ failure of
known sepsis origin [5]. In contrast, our study was conducted
in a mixed medical/surgical ICU where the patients were
admitted with medical problems, non-cardiovascular surgeries
or trauma, and where established infection was a common rea-
son for admission (33%). In addition, the intervention did not
significantly decrease the rate of ICU-acquired infections
(33.2% in the intensive insulin group compared with 27.17%
in the standard insulin group). These findings suggest that pre-
vention of nosocomial infections, more than control of estab-
lished ones, could be a major mechanism for the mortality
reduction in patients treated with strict glucose control. Fur-
thermore, the recently finished Volume Substitution and Insulin
Therapy in Severe Sepsis trial, a randomised multicentre trial
designed to assess the efficacy and safety of intensive insulin
therapy in patients with severe sepsis and septic shock, was
stopped early for safety reasons [16]. Of the 537 evaluated
patients there was no significant difference between the two
groups in the 28-day mortality rate or the mean organ failure
score. The rate of severe hypoglycaemia, however, was higher
in the intensive insulin therapy group compared with the stand-
ard insulin therapy group (17.0% vs. 4.1%, p < 0.001).
Table 2
Insulin therapy and control of blood glucose levels.
Variable Standard treatment (N = 250) Intensive treatment (N = 254) P value †
Administration of insulin (%) 118 (47) 246 (97) < 0.001
Insulin dose (IU/day) * 12.5 ± 32.8 52.4 ± 53.3 < 0.001




















Number of blood glucose measurement per day * 5.9 ± 4 13 ± 5.5 < 0.001
Number of patients in which morning median blood glucose was 
in their preset range (%)
43 (17.2) 100 (39.4) < 0.001
Hypoglycaemia ≤ 40 mg/dl (%) 2 (0.8) 21 (8.3) < 0.001
* Values presented as mean ± SD. Hypoglycaemia are number of patients with at least one episode over total number of patients per group.
† P values were determined wit the use of Student's t-test, Mann-Whitney test or Chi-square test as appropriate.
‡ To convert the values for glucose to millimoles per litre, multiply by 0.05551.Page 6 of 9
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Table 3
Causes of morbidity in the patient group
Variable Standard treatment (n = 250) Intensive treatment (n = 254) P value†
Length of stay in ICU (days)
Median (Interquartile range) 6 (3 to 11) 6 (3 to 12) 0.351
Duration of ventilatory support (days)
Median (Interquartile range) 5 (2 to 9) 6 (2 to 10) 0.857
Ventilatory support (%) 238 (95.2) 238 (93.7) 0.476
Dopamine (%) 190 (76) 182 (71.7)
Dosage (μg/kg/minute) *‡ 14.45 ± 8.97 14.85 ± 8.99 0.366
Norepinephrine (%) 68 (27.2) 55 (21.7)
Dosages (μg/kg/minute) *‡ 0.36 ± 0.77 0.36 ± 0.56 0.993
Epinephrine (%) 44 (17.6) 46 (18.1)
Dosages (μg/kg/minute) *‡ 0.34 ± 0.40 0.31 ± 0.59 0.613
Dobutamine (%) 9 (3.6) 14 (5.5)
Dosages (μg/kg/minute) *‡ 4.97 ± 2.43 8.43 ± 6.48 0.060
Swan Ganz (%) 28 (11.2) 30 (11.8) 0.800
Renal impairment (%) § 25 (10) 32 (12.6) 0.357
Renal-replacement therapy (%) 33 (13) 27 (10.8) 0.447
Hydrocortisone (%) 66 (26.4) 67 (26.3) 0.996
Ventilator associated pneumonia (%) 55 (22) 43 (16.9) 0.15
Catheter-related infection (%) 9 (3.6) 6 (2.4) 0.414
Urinary infections (%) 11 (4.4) 13 (5.1) 0.705
Primary bacteraemia (%) 8 (3.2) 7 (2.8) 0.769
Treatment with antibiotics for ≥ 8 days (%) 183 (73.2) 186(73.2) 0.994
Red-cell transfusions
Patients requiring transfusions (%) 91 (36) 99 (39) 0.551
No. of transfusions/patients* 6 ± 5.5 4.9 ± 4.1 0.412
* Values presented as mean ± SD.
† P values were determined wit the use of Student's t-test, the chi-square test or Fischer test as appropriate.
‡ Maximal dosage per day
§Renal impairment: peak plasma creatinine > 2.5 mg/dl, Peak plasma urea nitrogen > 60 mg/dl, dialysis or continuous venovenous 
haemofiltration.
Table 4
Causes of mortality in the patient group
Variable Standard treatment (N = 250) Intensive treatment (N = 254) Relative risk 
(95% confidence interval)
28-day deaths 81 (32.4) 93 (36.6) 1.1 (0.85 to 1.42)
Death in the intensive care unit (%) 78 (31.2) 84 (33.1) 1.06 (0.82 to 1.37)
In-hospital death (%). 96 (38.4) 102 (40) 1.05 (0.84 to 1.3
Death with history of diabetes 9 of 29 (31) 12 of 32 (37.5) 1.21 (0.60 to 2.40)
Critical Care    Vol 12 No 5    De La Rosa et al.The patients in our study were younger (47 years old) than in
other studies (63 years old) [5,6], and on admission to the ICU
the mean APACHE II score was lower in our study compared
with the medical ICU study by Van den Berghe and colleagues
(15 vs. 23) [6]. In addition, our population was relatively
healthy before the acute process that indicated ICU admis-
sion, as less than 14% of them had a significant concomitant
disease before admission. Thus, our study population may not
be critically ill enough to obtain a benefit from intensive insulin
therapy.
The patients in the intensive group in our study did not reach
the normal glucose level because our protocols were carefully
designed to avoid a high rate of hypoglycaemia. Therefore, this
strict control against hypoglycaemia could also become a
measure favouring the balance in glucose goals between the
groups. Furthermore, the mean values for glucose level in the
standard group were lower than expected because our
patients did not routinely receive a 10% dextrose infusion, and
a lower amount of parenteral calories was supplied from the
beginning. Thus, the median difference in glucose values
between groups was about 30 mg/dl and although this differ-
ence was statistically significant, there was a considerable
overlap between the two study groups (Figure 3). Such a rel-
atively small effect over glucose control could be one of the
reasons no differences were seen in morbidity or mortality
rates.
In addition, we observed a large variability of blood glucose
concentration in both groups, which has been suggested as
another possible explanation for the lack of beneficial effects
of insulin therapy [17]. The delay in the recruitment, much
longer than the studies by Van den Berghe and colleagues
[5,6], may explain our findings as it is possible that any benefit
may only be accrued early on.
Severe hypoglycaemia of 40 mg/dl or less was associated
with the application of insulin in our setting, as well as in the
cardiovascular surgical ICU study [5], but less frequent than in
the medical ICU study [6]. Hypoglycaemia of 60 mg/dl or less
was also more frequently associated with the utilisation of
insulin in the intensive group 66% compared with 10% in the
conventional group.
There were some limitations in our research. These were
related to sample size, which was underpowered to detect
both overall differences and those within subgroups. At the
time when we planned and conducted our study the only avail-
able information about efficacy was inferred from the first trial
by Van Den Berghe and colleagues [5], which showed a
42.5% relative risk reduction over a mortality rate in the control
group of about 8%. Based on these data, we assumed the
same relative risk reduction but over a higher expected mortal-
ity in the control group (i.e. 25%). Therefore, our study is not
large enough to say that there was no benefit in the overall
population or in the subgroups of medical or trauma/surgery
patients. On the other hand, the inability to maintain the blind-
ing because the titration of insulin required monitoring of glu-
cose levels may be a potential source of bias. In order to
decrease this problem, those physicians evaluating ICU-
acquired infections were blinded to the study group. Finally,
this study was performed in only one centre, an obvious con-
straint to generalise our results.
Conclusion
We found that strict glucose control did not decrease morbid-
ity or mortality in patients hospitalised in a mixed medical/sur-
gical ICU. Instead, the intervention produced an important
increase in severe hypoglycaemia. Of note, however, was that
it was very difficult to strictly restrict glycaemic control and the
study showed that less than 50% of patients were within tar-
get range. Therefore, the combination of an insufficient differ-
ence between the treatment groups in blood glucose values
and lack of power makes it impossible to draw any conclusion
on the efficacy of tight glycaemic control. Multicentre studies
are required to confirm these findings.
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